Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.45 |
| ▸ | ITGAL | P20701 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925193 | 0.95 | CKS1B (0.51) | SYKSUV39H2RETCKS1BSKP1 | |
| SCHEMBL6926466 | 0.90 | SYK (0.49) | SYKSUV39H2BTKJAK3AURKA | |
| SCHEMBL6926954 | 0.89 | CKS1B (0.56) | SYKRETBTKJAK3AURKA | |
| SCHEMBL6924929 | 0.79 | CNR2 (0.39) | SYKRET | |
| SCHEMBL6928230 | 0.78 | CNR2 (0.45) | RET | |
| SCHEMBL1350283 | 0.78 | JAK3 (0.56) | SYKSUV39H2RETBTKJAK3 | |
| SCHEMBL1350284 | 0.78 | JAK3 (0.56) | SYKSUV39H2RETBTKJAK3 | |
| SCHEMBL6920372 | 0.77 | CNR2 (0.50) | RET | |
| SCHEMBL6928989 | 0.77 | PIM1 (0.45) | SYKRET | |
| SCHEMBL529863 | 0.75 | MAP4K4 (0.58) | SYKSUV39H2RETBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | SYK 1353/4885SUV39H2 2735/4885RET 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.